Cytotoxic chemotherapy for pregnancy-associated breast cancer: single institution case series
| Autor: | Patrick G Morris, Fionnuala King, M. John Kennedy |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Oncology
Adult medicine.medical_specialty Databases Factual medicine.medical_treatment Biopsy Antineoplastic Agents Breast Neoplasms Gestational Age Occupational safety and health Breast cancer Pregnancy Internal medicine Epidemiology of cancer medicine Humans Pharmacology (medical) Breast Fetal Death Retrospective Studies Chemotherapy business.industry Pregnancy Outcome Cancer Abnormalities Drug-Induced Cytotoxic chemotherapy medicine.disease Delivery Obstetric Magnetic Resonance Imaging Female business Pregnancy Complications Neoplastic Rare disease |
| Zdroj: | Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 15(4) |
| ISSN: | 1477-092X |
| Popis: | Background. Pregnancy-associated (PA) breast cancer is a rare disease state that poses unique management challenges, specifically controlling the cancer and maximizing the survival of the expectant mother balanced with the health and safety of the developing fetus. As more women delay pregnancy into their 30s and 40s it is expected that this may become a more important clinical problem in the future. Existing data on PA-breast cancer comes from case series using older chemotherapy drugs. A review of practice was carried out to assess current experience with PA-breast cancer, particularly relating to current cytotoxic drugs and targeted agents. Methods. The St James’s Hospital breast cancer registry, a prospectively maintained database, was used to identify cases of PA-breast cancer over a 6.5-year period and a chart review carried out. Chemotherapy administered during pregnancy, breast cancer specific outcomes, and fetal outcomes were assessed. Results. Five patients were identified with PA-breast cancer; median age 34 years (range 28—35). The median gestation at presentation was 18 weeks (range 14—29). Four women received chemotherapy during pregnancy; three received doxorubicin and cyclophosphamide (AC) and one paclitaxel. These agents were generally well tolerated. At median gestation of 36 weeks (range 35—40 weeks) four elective caesareans and one spontaneous delivery occurred. There were no fetal abnormalities. Conclusions. Common cytotoxics can safely be delivered in pregnancy. Further research on newer therapies such as trastuzumab is needed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|